337 related articles for article (PubMed ID: 36005167)
21. MicroRNAs Associated with Von Hippel-Lindau Pathway in Renal Cell Carcinoma: A Comprehensive Review.
Schanza LM; Seles M; Stotz M; Fosselteder J; Hutterer GC; Pichler M; Stiegelbauer V
Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29165391
[TBL] [Abstract][Full Text] [Related]
22. Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions.
Atkins MB; Clark JI; Quinn DI
Ann Oncol; 2017 Jul; 28(7):1484-1494. PubMed ID: 28383639
[TBL] [Abstract][Full Text] [Related]
23. Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy.
Calvo E; Schmidinger M; Heng DY; Grünwald V; Escudier B
Cancer Treat Rev; 2016 Nov; 50():109-117. PubMed ID: 27664394
[TBL] [Abstract][Full Text] [Related]
24. Recent developments in small molecule therapies for renal cell carcinoma.
Song M
Eur J Med Chem; 2017 Dec; 142():383-392. PubMed ID: 28844802
[TBL] [Abstract][Full Text] [Related]
25. Check point inhibitors a new era in renal cell carcinoma treatment.
Alsharedi M; Katz H
Med Oncol; 2018 May; 35(6):85. PubMed ID: 29728867
[TBL] [Abstract][Full Text] [Related]
26. Advanced renal cell carcinoma: current and emerging management strategies.
Escudier B
Drugs; 2007; 67(9):1257-64. PubMed ID: 17547470
[TBL] [Abstract][Full Text] [Related]
27. The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma.
Shin SJ; Jeon YK; Cho YM; Lee JL; Chung DH; Park JY; Go H
Oncologist; 2015 Nov; 20(11):1253-60. PubMed ID: 26424759
[TBL] [Abstract][Full Text] [Related]
28. Molecular pathways in renal cell carcinoma: recent advances in genetics and molecular biology.
Su D; Singer EA; Srinivasan R
Curr Opin Oncol; 2015 May; 27(3):217-23. PubMed ID: 25811348
[TBL] [Abstract][Full Text] [Related]
29. Molecular mechanisms of resistance to tyrosine kinase inhibitor in clear cell renal cell carcinoma.
Sekino Y; Teishima J; Liang G; Hinata N
Int J Urol; 2022 Dec; 29(12):1419-1428. PubMed ID: 36122306
[TBL] [Abstract][Full Text] [Related]
30. Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas.
Roskoski R
Pharmacol Res; 2017 Jun; 120():116-132. PubMed ID: 28330784
[TBL] [Abstract][Full Text] [Related]
31. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors.
Shah AY; Kotecha RR; Lemke EA; Chandramohan A; Chaim JL; Msaouel P; Xiao L; Gao J; Campbell MT; Zurita AJ; Wang J; Corn PG; Jonasch E; Motzer RJ; Sharma P; Voss MH; Tannir NM
Eur J Cancer; 2019 Jun; 114():67-75. PubMed ID: 31075726
[TBL] [Abstract][Full Text] [Related]
32. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
Rabjerg M
Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
[TBL] [Abstract][Full Text] [Related]
33. Targeting oxidative phosphorylation to increase the efficacy of immune-combination therapy in renal cell carcinoma.
Tian J; Luo J; Zeng X; Ke C; Wang Y; Liu Z; Li L; Zhang Y; Hu Z; Yang C
J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38355278
[TBL] [Abstract][Full Text] [Related]
34. Immune approaches beyond traditional immune checkpoint inhibitors for advanced renal cell carcinoma.
Jang A; Lichterman JN; Zhong JY; Shoag JE; Garcia JA; Zhang T; Barata PC
Hum Vaccin Immunother; 2023 Dec; 19(3):2276629. PubMed ID: 37947202
[TBL] [Abstract][Full Text] [Related]
35. Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma.
Ghatalia P; Zibelman M; Geynisman DM; Plimack ER
Curr Treat Options Oncol; 2017 Jan; 18(1):7. PubMed ID: 28210995
[TBL] [Abstract][Full Text] [Related]
36. Everolimus (RAD001) in the treatment of advanced renal cell carcinoma: a review.
Agarwala SS; Case S
Oncologist; 2010; 15(3):236-45. PubMed ID: 20215359
[TBL] [Abstract][Full Text] [Related]
37. Update on immunotherapy for renal cancer.
Canales Rojas R
Medwave; 2021 Jun; 21(5):e8202. PubMed ID: 34214067
[TBL] [Abstract][Full Text] [Related]
38. The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis.
Mori K; Abufaraj M; Mostafaei H; Quhal F; Fajkovic H; Remzi M; Karakiewicz PI; Egawa S; Schmidinger M; Shariat SF; Gust KM
Eur Urol; 2021 Jun; 79(6):783-792. PubMed ID: 33172722
[TBL] [Abstract][Full Text] [Related]
39. Future treatment options in metastatic clear cell renal cell carcinoma.
Simonaggio A; Auvray-Kuentz M; Rochand A; Thibault C; Gervais C; Oudard S; Vano YA
Bull Cancer; 2022 May; 109(2S):2S47-2S58. PubMed ID: 35760471
[TBL] [Abstract][Full Text] [Related]
40. Current State of Systemic Therapies for Advanced Renal Cell Carcinoma.
Gulati S; Vaishampayan U
Curr Oncol Rep; 2020 Feb; 22(3):26. PubMed ID: 32048058
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]